Ovarian cancer is developed by uncontrollable growth of cells in ovaries. Made up of three different types of cells, ovaries may develop three different types of tumors. Majority of these tumors are non-cancerous, which can be treated by removing either part of the ovary containing the tumor, or by removing the ovary itself.
The American Cancer Society estimates that approx. 20,000 women will be diagnosed with ovarian cancer in the U.S. and more than 14,000 will lose their lives because of it in 2017 alone.
In terms of deaths, this form of cancer ranks fifth and it led to more deaths than any other female reproductive system form of cancer. The chance of a women developing ovarian cancer during her life is 1 in 75 and the chance of her dying is 1 in 100. It is mainly seen in older women above the age of 63 years.
Even though the rate at which women have been diagnosed with ovarian cancer has been falling, it is still a public health menace that needs to be tackled effectively.
This is where the ovarian cancer diagnostics market can play a crucial role. The global ovarian cancer diagnostics market is predicted to grow with a CAGR of 8.7% and be worth nearly US$ 1 billion in 2022, from less than US$ 640 million in 2017.
Epithelial Tumours Segment larger than the other two combined
The Epithelial Tumours Segment is anticipated to grow to almost US $ 880 million by the end of the forecast period and it already accounts for an 11% revenue share in 2017 itself.
North America alone represents almost 2/5th of the market and it should touch US$ 330 million by the end of 2022. The germ cell carcinoma tumors segment is much smaller by comparison and is only poised to be a US$ 50 million market by the end of the five-year study.
Even the stromal carcinoma tumors segment is marginal at best when contrasted with epithelial tumors in the ovarian cancer diagnostics market. The stromal carcinoma tumors segment is likely to be valued at only US$ 28 million in 2017.
Know More Details About the Report
Hospital associated and independent diagnostic labs most vital
The hospital associated lab segment is expected to record a CAGR of 7.8% from 2017-2022 and rise from just under $300 million in 2017 to roughly US$ 440 million in 2022.
Independent diagnostic labs are the second most important segment in the ovarian cancer diagnostics market and are estimated to be worth US$ 161 million in 2017.
While North America might account for the largest contribution, Europe should record a higher CAGR of 9.5% making it more attractive to target in the long term.
Focus on CA 125 test segment in the ovarian cancer diagnostics market
The CA 125 test segment could be worth roughly US$ 440 million in 2022 and some key stakeholders may decide to focus on this lucrative test over all other available alternatives in the ovarian cancer diagnostics market. However, the HER 2 segment also accounts for a 3.1% revenue share in 2017 and it would be unwise to do so.
On the other hand, the BRCA segment in North America alone could grow with a CAGR of 8.3% for the period 2017-2022, making it imperative for companies to hedge their bets in the ovarian cancer diagnostics market.
Avail customized purchase options for your needs
The report has also profiled leading players in the global market for ovarian cancer diagnostics, which include
- Quest Diagnostics Incorporated
- Myriad Genetics Inc.
- AstraZeneca plc.
- Epigenomics AG
- Illumina Inc.
- Bio-Rad Laboratories Inc.
- Siemens AG
- Thermo Fisher Scientific Inc.
- Roche Holding AG.
- Abbott Laboratories.
An Adaptive Approach to Modern-day Research Needs
(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)
Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for ovarian cancer.
Rising number of deaths caused by ovarian cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease.
In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of ovarian cancer. For public administration authorities, compelling people to avoid such lifestyles is like challenging the status quo.
The burden of controlling the incidence of ovarian cancer gets passed on to hospitals & medical research organizations as they strive to develop novel diagnostic and therapeutic procedures.
The report on the global market for ovarian cancer discusses such key factors that govern the economics of ovarian cancer diagnostics across the globe. Some of the key influences for the growth of global ovarian cancer diagnostics market include:
- rising presence of carcinogenic elements in common consumables
- surging exposure to toxic substances in factories & industrial settings
- lack of awareness related to causes, symptoms, and preventive measures for ovarian cancer
- high healthcare costs, deterring ovarian cancer patients from seeking optimum diagnosis
With growing incidence of ovarian cancer, the future generations will witness a more accessible, affordable, and diagnosis-associated treatment for ovarian cancer.
As ovarian cancer research organizations & societies struggle to develop effective medications in tight-budgeted capitals, governments are deploying initiatives that boost the awareness of ovarian cancer.
Need for Premeditated Ovarian Cancer Patient Compliance
Ovarian cancer patients are often riddled with confusing options for diagnosis. Choosing the right screening test can become a dilemma for the patient and his/her family.
Companies manufacturing medical instruments and devices for diagnosis of ovarian cancer are expected to mitigate such difficulties by facilitating a well-laid patient compliance regime.
The global market for ovarian cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings.
Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of ovarian cancer patients.
Key players in the global ovarian cancer diagnostics market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on ovarian cancer patients.
Such cooperative efforts are of paramount importance in the global ovarian cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.
Ovarian Cancer diagnostics market – Regional Overview & Competitive Backdrop
A comprehensive section on the regional analysis of global ovarian cancer diagnostics market is included in the report. North America, Europe, Japan, Asia-Pacific excluding Japan (APEJ), Latin America, and Middle East & Africa are key regions into which the expansion of global ovarian cancer diagnostics market is studied.
Developed markets with robust healthcare infrastructures are deemed lucrative for patients seeking diagnosis for ovarian cancer. On the other hand, higher resource availability, cheap wages, and lenient manufacturing regulations in developing regions attract the attention of manufacturers of ovarian cancer diagnosis instruments.
In the report, there is an elaborate section on the competitive landscape of global ovarian cancer diagnostics market. This part profiles key players in the global market, which includes leading manufacturers of diagnostic devices and related medical apparatus.
The scalability employed in profiling these players includes criteria such as the company’s contribution to global ovarian cancer diagnostics market revenues, recent mergers & acquisitions involving the company, and new product launches.
Through this report, companies can also understand the investment standpoint in the global ovarian cancer diagnostics market, which can be further inferred while taking insightful actions.
Fact.MR is committed to offer unbiased and independent market research solutions to its clients.
Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,
- Primary research
- Secondary research
- Trade research
- Focused interviews
- Social media analysis
Need an Exclusive Report for your Unique Requirement?
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.